139 related articles for article (PubMed ID: 36921808)
1. LInezolid Monitoring to MInimise Toxicity (LIMMIT1): A multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring.
Lau C; Marriott D; Bui J; Figtree M; Gould M; Chubaty A; Su Y; Adhikari S; Konecny P; Kozierowski K; Holland T; Milliken E; Akram A; Mcnamara A; Sun Y; Van Hal S; Patanwala AE; Shahabi-Sirjani A; Gray T; Yeo CY; Netluch A; Halena S; Appay M; Alameddine R; Yin F; Nguyen Q; So MY; Sandaradura I; Kim HY; Galimam S; Cerruto N; Lai T; Gilbey T; Daveson K; Reuter SE; Penm J; Alffenaar JW
Int J Antimicrob Agents; 2023 May; 61(5):106783. PubMed ID: 36921808
[TBL] [Abstract][Full Text] [Related]
2. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study.
Cojutti PG; Merelli M; Bassetti M; Pea F
J Antimicrob Chemother; 2019 Dec; 74(12):3588-3595. PubMed ID: 31504570
[TBL] [Abstract][Full Text] [Related]
3. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.
Pea F; Viale P; Cojutti P; Del Pin B; Zamparini E; Furlanut M
J Antimicrob Chemother; 2012 Aug; 67(8):2034-42. PubMed ID: 22553142
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients.
Dai Y; Jiang S; Chen X; Han L; Zhang C; Yu X; Zhang X
J Clin Pharm Ther; 2021 Jun; 46(3):807-813. PubMed ID: 33555057
[TBL] [Abstract][Full Text] [Related]
6. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.
Crass RL; Cojutti PG; Pai MP; Pea F
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109977
[TBL] [Abstract][Full Text] [Related]
7. A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?
Pea F; Cojutti PG; Baraldo M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):303-308. PubMed ID: 28419737
[TBL] [Abstract][Full Text] [Related]
8. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.
Niwa T; Suzuki A; Sakakibara S; Kasahara S; Yasuda M; Fukao A; Matsuura K; Goto C; Murakami N; Itoh Y
Clin Ther; 2009 Oct; 31(10):2126-33. PubMed ID: 19922883
[TBL] [Abstract][Full Text] [Related]
9. Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions.
Cheng CN; Wu CC; Kuo CH; Wang CC; Wang JT; Lin YT; Jhang RS; Lin SW
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):466-475. PubMed ID: 32600864
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients.
Wicha SG; Mair A; Chiriac U; Frey OR; Fuchs T; Gaasch M; Hagel S; Richter DC; Roberts JA; Röhr AC; Weigand MA; Brinkmann A
Int J Antimicrob Agents; 2022 May; 59(5):106572. PubMed ID: 35307562
[TBL] [Abstract][Full Text] [Related]
11. Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study.
Kim HS; Lee E; Cho YJ; Lee YJ; Rhie SJ
J Clin Pharm Ther; 2019 Feb; 44(1):84-90. PubMed ID: 30243033
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for linezolid-induced thrombocytopenia in patients without haemato-oncologic diseases.
Choi GW; Lee JY; Chang MJ; Kim YK; Cho Y; Yu YM; Lee E
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):228-234. PubMed ID: 30171804
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients.
Dong HY; Xie J; Chen LH; Wang TT; Zhao YR; Dong YL
Eur J Clin Microbiol Infect Dis; 2014 Jun; 33(6):1029-35. PubMed ID: 24515096
[TBL] [Abstract][Full Text] [Related]
14. Initial trough concentration may be beneficial in preventing linezolid-induced thrombocytopenia.
Komatsu T; Nakamura M; Uchiyama K; Inoue G; Sakanoue K; Kawamura A; Hiratsuka K; Takayama Y; Takaso M; Atsuda K
J Chemother; 2022 Oct; 34(6):375-380. PubMed ID: 35209803
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination.
Kaya Kılıç E; Bulut C; Sönmezer MÇ; Ozel Ö; Ataman Hatipoğlu Ç; Tuncer Ertem G; Tülek N; Kınıklı S
J Infect Dev Ctries; 2019 Oct; 13(10):886-891. PubMed ID: 32084018
[TBL] [Abstract][Full Text] [Related]
16. Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study.
Thi Phuong Thao L; Duc Trung N; Thi My L; Minh Hong L; Viet Hoan B; Quang Hung V; Dang Hai P
J Infect Dev Ctries; 2024 Feb; 18(2):285-290. PubMed ID: 38484357
[TBL] [Abstract][Full Text] [Related]
17. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
Nukui Y; Hatakeyama S; Okamoto K; Yamamoto T; Hisaka A; Suzuki H; Yata N; Yotsuyanagi H; Moriya K
J Antimicrob Chemother; 2013 Sep; 68(9):2128-33. PubMed ID: 23625638
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients.
Hirano R; Sakamoto Y; Tachibana N; Ohnishi M
Int J Clin Pharm; 2014 Aug; 36(4):795-9. PubMed ID: 24913359
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia.
Hanai Y; Matsuo K; Ogawa M; Higashi A; Kimura I; Hirayama S; Kosugi T; Nishizawa K; Yoshio T
J Infect Chemother; 2016 Aug; 22(8):536-42. PubMed ID: 27321773
[TBL] [Abstract][Full Text] [Related]
20. Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more.
Xu Y; Yang X; Liang P; Qu C
BMC Infect Dis; 2023 Nov; 23(1):840. PubMed ID: 38030977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
